Strensiq: A Breakthrough in Accessing Progressive Remedy for Hypophosphatasia within the Higher Bay Space

The hypophosphatasia drug Strensiq was first launched within the Higher Bay Space beneath the coverage of “entry to medicines and gadgets from Hong Kong and Macao”

Making new medication extra accessible to sufferers with this uncommon illness

AstraZeneca China has introduced that, primarily based on the coverage of “Hong Kong and Macao Drug and Machine Clearance”, its progressive drug Strensiq (generic title: asforzyme) within the discipline of uncommon ailmentsAInjection/asfotase alfa) has been permitted by the Guangdong Provincial Meals and Drug Administration and has been formally launched to designated medical establishments within the Higher Bay Space to be used as long-term enzyme substitute remedy for sufferers with infantile-onset hypophosphatasia (HPP). , to deal with the skeletal manifestations of the illness. This primary approval within the Higher Bay Space acknowledges the superior scientific software of the drug. Kids in mainland China will be capable of use the drug at designated medical establishments within the Higher Bay Space with out leaving the nation, which alleviates the issue of Chinese language sufferers who’re in pressing want of it. of medicine.

Hypophosphatasia is a particularly uncommon, progressive, hereditary metabolic illness. Sufferers lack alkaline phosphatase (ALP), which impacts bone mineralization and manufacturing, leading to bone progress and energy. Issues can happen and trigger different problems, equivalent to fractures, bone ache, and problem strolling and respiratory, epilepsy, and many others., which may trigger lifelong issues and severely have an effect on the standard of life.[1].

It’s the first and solely* enzyme substitute remedy on the planet permitted for the therapy of hypophosphatasia.[2]asphoraAThe energetic substances contained within the injection can change the lacking alkaline phosphatase within the affected person’s physique and act as a long-term enzyme substitute remedy to regulate the affected person’s symptoms1. 4 potential open-label scientific research have evaluated and confirmed the efficacy of asforase in sufferers with perinatal, childish or early childhood hypophosphatasia.AScientific efficacy and security of injections. Kaplan-Meier evaluation of total survival in sufferers with perinatal/childish onset hypophosphatasia handled with the drug (37 sufferers) versus historic management sufferers with hypophosphatasia (48 sufferers) discovered that SulfaseAInjections can considerably enhance affected person survival charges. Research have proven that by asferaseAThe survival price of sufferers handled with the injection was 95% at age 1 yr, and the survival price of sufferers within the historic management group was 42%;AThe three.5-year survival price of sufferers handled with injections was 86%, whereas the survival price of sufferers within the historic management group was 27%;AThe survival price of sufferers injected at age 5 years was 82%, in contrast with 27% of sufferers within the historic management group.[3]. For newborns and babies, asforaseAThe injection helps reverse the signs of hypomineralization[4],[5],[6]. In pediatric sufferers, asphoraseAThe injection could assist sufferers obtain a whole or substantial remedy for hypophosphatasia-related rickets.[7].

Enzyme substitute remedy is an internationally acknowledged efficient therapy technique for the reason for hypophosphatasia. It may be used as a first-line therapy technique, particularly for younger sufferers and people with apparent signs.[8]Nevertheless, the accessibility of associated medication has all the time been an enormous downside for sufferers. This time console yourselvesAThe injection was the primary to be permitted within the Higher Bay Space, and represents a serious advance within the therapy of hypophosphatasia in China and presents new hope for therapy for home youngsters with inherited hypophosphatasia.

Lin Xiao, Normal Supervisor of AstraZeneca’s China Biopharmaceutical Enterprise and Head of Hong Kong and MacauHe stated: “With greater than 30 years of expertise in China, AstraZeneca has a deep understanding of the unmet wants of Chinese language sufferers. This time, AstraZenecaABenefiting from the help of the Hong Kong-Macao Drug and Machine Join Coverage, the injection has been permitted for introduction within the Higher Bay Space for the primary time, lowering the therapy wait time for Chinese language sufferers with hypophosphatasia to make use of progressive medicines globally. Going ahead, we’ll proceed to work with all companions to speed up the introduction of worldwide main progressive medicines urgently wanted by sufferers within the nation throughout the Higher Bay Space, benefiting extra Chinese language sufferers.”

Hu Yiqing, Vice President of AstraZeneca China and Head of Uncommon Ailments DivisionHe stated: “‘Affected person-centered’, AstraZeneca not solely actively participates and continues to discover the sphere of uncommon ailments, however can also be dedicated to becoming a member of forces with a number of events to resolve the dilemma of drug shortages for Chinese language uncommon illness sufferers and enhance the accessibility of progressive medicines. Working laborious At present, we’re very comfortable to see AsforaseAThe injection was first permitted for introduction within the Higher Bay Space, enabling Chinese language sufferers with hypophosphatasia to speed up entry to globally main medicines. Sooner or later, AstraZeneca will proceed to connect nice significance to the unmet wants of sufferers with hypophosphatasia and different uncommon ailments, take a number of measures to speed up the introduction and accessibility of progressive medicines, and unite all events to help the development and enchancment of uncommon ailments. analysis and therapy within the Chinese language ecosystem, allow us to stroll hand in hand and light-weight up the sunshine of life. “

*As of August 2024, taken from www.fda.gov, www.ema.europa.eu,

Disclaimer: The medication and indications concerned on this data haven’t been permitted in mainland China. AstraZeneca doesn’t suggest the usage of unapproved medication.

About Hypophosphatasia

Hypophosphatasia is an inherited, power, progressive, life-threatening metabolic dysfunction that has devastating results on a number of physique techniques, resulting in debilitating or life-threatening problems.[9]Hypophosphatasia is characterised by low alkaline phosphatase (ALP) exercise and faulty bone mineralization, which may result in bone destruction and deformity and different skeletal abnormalities, in addition to systemic problems equivalent to muscle weak point and respiratory failure, resulting in untimely dying in neonates 4 ,8,[10].

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a number one international biopharmaceutical firm that focuses on the invention, growth, manufacturing and commercialisation of prescription medicines, with a give attention to oncology, uncommon ailments, and circumstances together with cardiovascular, renal and metabolic, respiratory and immune. Together with biopharmaceuticals and different fields. AstraZeneca’s international headquarters are positioned in Cambridge, UK, with operations in additional than 100 international locations worldwide. Its progressive medicines profit hundreds of thousands of sufferers worldwide.

About AstraZeneca China

Since AstraZeneca entered China in 1993, it has centered on the therapy areas with probably the most pressing wants of Chinese language sufferers, together with oncology, cardiovascular, renal, metabolism, respiratory, digestive, uncommon ailments, vaccine antibody and autoimmunity, and many others., and has developed greater than 40 progressive merchandise delivered to China. AstraZeneca’s China headquarters and China international R&D middle are positioned in Shanghai. It has established international manufacturing and provide bases in Wuxi, Taizhou and Qingdao, and has provided high-quality medicines to just about 70 international markets. Lately, the corporate has established regional headquarters in Beijing, Guangzhou, Hangzhou, Chengdu and Qingdao. AstraZeneca can also be working with companions to construct a diversified innovation “troika”, together with the China Good Well being Innovation Middle (CCiC), the Worldwide Life Sciences Innovation Park (iCampus) and the AstraZeneca CICC Medical Business Fund. The worldwide progressive healthcare ecosystem will collectively promote the speedy growth of the regional financial system and the general healthcare business. At present, China has turn out to be the world’s second largest marketplace for AstraZeneca.

Prescribing data for Strensiq Hong Kong (40 mg), April 2023 model (Chinese language) ↑

Scott LJ. Asfotase Alfa: a evaluate of pediatric-onset hypophosphatasia. Medication. 2016 Feb;76(2):255-62. doi: 10.1007/s40265-015-0535-2. ↑

Kaplan-Meier evaluation of survival in sufferers with perinatal and childish hypophosphatasia. Sufferers handled with Asfotase alfa (research ENB-002-08/ENB-003-08 and ENB-010-10) had a considerably improved survival price, calculated utilizing the Kaplan-Meier product restrict estimate, in contrast with historic controls (examine ENB-011-10; P .0001, Kaplan-Meier log-rank take a look at). ↑

Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme substitute remedy in life-threatening hypophosphatasia. N Engl J Med. 2012;366(10):904-913. ↑

Whyte MP, Simmons JH, Moseley S, et al. Asfotase alfa for infants and younger youngsters with hypophosphatasia: 7-year outcomes from a single-arm, open-label, section 2 extension examine. Lancet Diabetes Endocrinol. 2019;7(2):93-105. ↑

Hofmann CE, Harmatz P, Vockley J, et al. Efficacy and security of asfotase alfa in infants and younger youngsters with hypophosphatasia: an open-label section 2 examine. J Clin Endocrinol Metab. ↑

Whyte MP, Madson KL, Phillips D, Reeves AL, McAlister WH, Yakimoski A, Mack KE, Hamilton Okay, Kagan Okay, Fujita KP, Thompson DD, Moseley S, Odrljin T, Rockman-Greenberg C. Asfotase alfa remedy for youngsters with hypophosphatasia. JCI Insights. 2016 June 16;1(9):e85971. doi: 10.1172/jci.perception.85971 ↑

Liu Min, Zhao Yun, Gong Chunxiu New advances in hypophosphatemia analysis[J]Chinese language Journal of Pediatrics,2019,57(11):899-903 ↑

Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(suppl 2):380-388. ↑

Fraser D. Hypophosphatasia. Am J Med. 1957;22(5):730-746. ↑